Bigfoot Biomedical Closes $55M Series C Financing, Plans FDA Filing For Diabetes System

Diabetes-care company Bigfoot Biomedical announced it raised $55m in a Series C round to support US FDA submission for its insulin delivery system.

Diabetes

Milipitas, CA-based Bigfoot Biomedical Inc. announced on 2 June it closed a $55m series C financing, which was led by Abbott Laboratories Inc. with support from existing investors including Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management and new investors including the Smile Group.

The company said it will use the proceeds from the financing to complete the product development and file for US...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Financing

More from Business